Plan the evidence behind the claim.
Turn a cellular-restoration objective into a draft framework for function, identity, safety, causality and durability.
Your draft framework
Select the context and claim, then build the brief. The output is a question-and-measurement framework requiring specialist review, not an approved study plan.
No brief generated yet.
Frame the question
Choose the biological function or development decision that matters.
Keep the context
Retain species, cell type, intervention direction and source limits.
Scope the work
Confirm expertise, data, rights, laboratory capacity and acceptance criteria.
Advance. Revise. Stop.
Use the evidence to choose a justified next action, including no action.
Scientific summaries are adapted from the supplied 15 October 2026 CRISPR Project Assessment. Source records show the original references and review access; this release is not a new systematic review.
C01 — Yin J, Gao Y, Jing Y, et al. CRISPR screening identifies GNPTAB as a noncanonical STING activator driving cellular senescence. Protein & Cell. 27 July 2026.C02 — Chen ACY, Ji KY, Yerinde C, et al. CRISPR screens identify targets to rescue age-related T cell dysfunction in cancer. Cell. 29 July 2026.C06 — Madsen A, Selfjord N, Martinez-Lage M, et al. Single-cell and in vivo profiling reveal heterogeneous and organ-specific CRISPR-Cas9 off-target and translocation outcomes. Nature Communications. 26 August 2026;17:9067.C07 — Hwang GH, Vyshedskiy B, Barry T, et al. Analysing long-read CRISPR experiments with CRISPRLungo. Nature Biomedical Engineering. 20 August 2026.C08 — Jung H, Devant P, Ching C, et al. Virus-like particles enable targeted gene engineering and pooled CRISPR screening in primary human myeloid cells. Nature Biotechnology. 17 August 2026.C12 — Lai C, Fu W, Liu J, et al. LMO7-mediated POLR2A degradation promotes cellular senescence through the MDM4/p53/p21 axis. Cell Death & Disease. 28 March 2026;17:421.